Columbia University faculty present research on a previously unknown type of immune cell in kidney tumors that can predict which patients are likely to have cancer recur after surgery.

Columbia University and Weill Cornell Medicine psychiatrists continue to investigate – in the clinic and in the lab – the potential role of ketamine in the treatment of resistant depression.

Columbia University pulmonologists conducts clinical trial on novel triple combination modulator for cystic fibrosis in patients with advanced lung disease, demonstrating progressive improvement in weight, lung function, and patient-reported outcomes.

Columbia University is one of the leading programs in the United States conducting a groundbreaking Phase 2 clinical trial of an investigational gene therapy for dry age-related macular degeneration.

NewYork-Presbyterian obstetricians and gynecologists continue to investigate COVID-19 and its potential impact on pregnancy outcomes, including studies on serial testing for SARS-CoV-2 and vaccinations.

Neurologists and critical care medicine specialists at NewYork-Presbyterian Hospital offer highly specialized expertise in disorders of consciousness to promote the best outcomes for patients.

Oncologists and other specialists at NewYork-Presbyterian Hospital continue to contribute their expertise and resources to scientific investigations of COVID-19 and its implications for oncology care.

Research by Adam Mor, MD, PhD, a rheumatologist and molecular immunologist at NewYork-Presbyterian/Columbia University Irving Medical Center, focuses on the function of T lymphocytes in autoimmune disease and cancer